Literature DB >> 9802540

Ursodeoxycholate alleviates alcoholic fatty liver damage in rats.

L Oliva1, F Beaugé, D Choquart, A M Montet, M Guitaoui, J C Montet.   

Abstract

The hydrophilic bile salt ursodeoxycholate (UDC) improves cholestasis in several liver diseases and is in vitro an efficient membrane stabilizer. However, its action on chronic ethanol-induced liver damage is not established. We thus sought to determine the effect of UDC on chronic ethanol-induced steatosis and on liver plasma membrane fluidity in rats. Male rats were pair-fed liquid diets containing 36% of calories as ethanol (alcohol diet) or an isocaloric maltose-dextrin mixture (control diet). Four groups of 10 animals received, respectively, during 30 days: the control diet, the control diet + UDC (90 mg/kg/day), the alcohol diet, and the alcohol diet + UDC. Bile was collected for assessment of bile flow, biliary lipids, and individual bile salts. Liver lipid contents and lipid peroxidation were determined. Plasma membrane fluidity was assessed by fluorescence polarization of various probes. Alcohol treatment caused a 4-fold increase in liver triacylglycerol and cholesterol ester levels. UDC supplementation significantly reduced these increases by 50% and 40%, respectively. UDC intake was associated with a marked decrease in alcohol-induced lipid peroxidation. Bile flow, bile salt, and phospholipid secretion were slightly increased by alcohol intake. The addition of UDC-enriched bile with tauroursodeoxycholate (38%) without significantly affecting the biliary parameters. Lastly, UDC treatment almost totally prevented the 20% increase in liver plasma membrane fluidity due to chronic alcohol intake. This study shows that UDC intake, concomitant with alcohol diet, exerts a clear-cut membrane protective effect that might alleviate ethanol-induced lipid disorders.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9802540

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  6 in total

1.  Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis.

Authors:  Susumu Itoh; Azuma Kanazuka; Takahide Akimoto
Journal:  Dig Dis Sci       Date:  2003-11       Impact factor: 3.199

2.  Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia.

Authors:  Jian-Gao Fan; Lan Zhong; Li-Yan Tia; Zheng-Jie Xu; Min-Sheng Li; Guo-Liang Wang
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

3.  Effect of ursodeoxycholic acid on hepatic steatosis in rats.

Authors:  Abdullah Okan; Huseyin Astarcioglu; Ethem Tankurt; Ozgul Sagol; Emel Altekin; Ibrahim Astarcioglu; Omur Gonen
Journal:  Dig Dis Sci       Date:  2002-11       Impact factor: 3.199

4.  Alteration of bile acid metabolism in the rat induced by chronic ethanol consumption.

Authors:  Guoxiang Xie; Wei Zhong; Houkai Li; Qiong Li; Yunping Qiu; Xiaojiao Zheng; Huiyuan Chen; Xueqing Zhao; Shucha Zhang; Zhanxiang Zhou; Steven H Zeisel; Wei Jia
Journal:  FASEB J       Date:  2013-05-24       Impact factor: 5.191

5.  Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitis.

Authors:  Torsten Diesinger; Vyacheslav Buko; Alfred Lautwein; Radovan Dvorsky; Elena Belonovskaya; Oksana Lukivskaya; Elena Naruta; Siarhei Kirko; Viktor Andreev; Dominik Buckert; Sebastian Bergler; Christian Renz; Edith Schneider; Florian Kuchenbauer; Mukesh Kumar; Cagatay Günes; Berthold Büchele; Thomas Simmet; Dieter Müller-Enoch; Thomas Wirth; Thomas Haehner
Journal:  PLoS One       Date:  2020-07-23       Impact factor: 3.240

Review 6.  Role of farnesoid X receptor and bile acids in alcoholic liver disease.

Authors:  Sharon Manley; Wenxing Ding
Journal:  Acta Pharm Sin B       Date:  2015-03-09       Impact factor: 11.413

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.